These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27668535)

  • 1. Potential blood clotting factors and anticoagulants.
    Jin NZ; Gopinath SCB
    Biomed Pharmacother; 2016 Dec; 84():356-365. PubMed ID: 27668535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing human blood clotting deficiency.
    Ong CC; Gopinath SCB; Rebecca LWX; Perumal V; Lakshmipriya T; Saheed MSM
    Int J Biol Macromol; 2018 Sep; 116():765-773. PubMed ID: 29775720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
    Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
    Makris M; Greaves M; Phillips WS; Kitchen S; Rosendaal FR; Preston EF
    Thromb Haemost; 1997 Mar; 77(3):477-80. PubMed ID: 9065997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
    Zivelin A; Rao LV; Rapaport SI
    J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood coagulation.
    Jackson CM; Nemerson Y
    Annu Rev Biochem; 1980; 49():765-811. PubMed ID: 6996572
    [No Abstract]   [Full Text] [Related]  

  • 11. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
    Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
    Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing individualized coagulation profiling of disease risk: thrombin generation dynamic models of the pro and anticoagulant balance.
    Brummel-Ziedins KE
    Thromb Res; 2014 May; 133 Suppl 1():S9-S11. PubMed ID: 24759148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphosphate modulates blood coagulation and fibrinolysis.
    Smith SA; Mutch NJ; Baskar D; Rohloff P; Docampo R; Morrissey JH
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):903-8. PubMed ID: 16410357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the action of factor VIIa in dilutional coagulopathy.
    Monroe DM
    Thromb Res; 2008; 122 Suppl 1():S7-S10. PubMed ID: 18691504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
    Tanaka KA; Szlam F; Rusconi CP; Levy JH
    Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snake-venom-derived Factor IX-binding protein specifically blocks the gamma-carboxyglutamic acid-rich-domain-mediated membrane binding of human Factors IX and X.
    Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
    Biochem J; 2007 Jul; 405(2):351-7. PubMed ID: 17407444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.
    Christensen TD; Jensen C; Larsen TB; Christiansen K; Sørensen B
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):358-65. PubMed ID: 19417631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.